Atlas Trials

Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone

Clinical trial NCT06388616 · COMPLETED

Trial details

NCT number
NCT06388616
Sponsor
AstraZeneca
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Hepatic Impairment
Start date
2024-05-02
Primary completion
2024-09-05
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.